Zhan Wang1, Juan Chen2,3, Mei-Zuo Zhong1, Juan Huang4, Yuan-Ping Hu4, De-Yun Feng5, Zhi-Jiao Zhou6, Xiao Luo7, Zhao-Qian Liu2,3, Wu-Zhong Jiang8, Wei-Bing Zhou9. 1. Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. 2. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. 3. Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410078, People's Republic of China. 4. Hunan Province Clinic Meditech Research Center for Breast Cancer, Changsha, 410008, People's Republic of China. 5. Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. 6. Department of Pathology, The third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. 7. Department of Pain, The third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. 8. Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. jwz903@126.com. 9. Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. zhouweibing298@163.com.
Abstract
PURPOSE: To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. METHODS: This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. RESULTS: Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. CONCLUSION: ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
PURPOSE: To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy. METHODS: This study enrolled 308 breast cancerpatients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed. RESULTS: Our results showed that ANLN expression was associated with survival of breast cancerpatients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancerpatients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy. CONCLUSION:ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancerpatients.
Entities:
Keywords:
ANLN; Anthracycline; Breast cancer; Prognosis